HIGHLIGHTS
- who: Joshua J. Neumiller et al. from the Department of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, USA have published the research work: GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease, in the Journal: (JOURNAL)
- what: Even with the standard-of-care use of ACE inhibitors and ARBs, which are widely underutilized in the overall DKD population, the residual risk for the progression of kidney disease and CV events persists.
- how: This review discusses current considerations for GLP-1 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.